Johnson & Johnson stock gains on Caplyta trial results

Published on 09/23/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock reached USD 269.57 on September 22, 2026, while UBS raised its target to USD 320. The 2026 sales midpoint is USD 101.1 billion.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground — Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) closed at USD 269.57 on the NYSE on September 22, 2026, after trading between USD 268.59 and USD 273.73. The company also has a fresh pharmaceutical catalyst: positive Phase III Caplyta results prompted UBS to raise its price target from USD 280 to USD 320.

UBS raises target to USD 320

According to Investing.com on September 22, 2026, UBS maintained a Buy rating and lifted its Johnson & Johnson target to USD 320 from USD 280 after positive Phase III results for Caplyta. The same report said Guggenheim raised its target to USD 287 from USD 270 while also retaining a Buy rating.

The change gives the UBS target a USD 40 increase, or 14.3 percent, from the previous level. For investors, the important operating question is whether Caplyta can add growth while Johnson & Johnson manages pressure on established medicines.

Sales guidance crosses USD 100 billion

Johnson & Johnson guides for 2026 reported sales of USD 101.1 billion at the midpoint, according to the September 22, 2026 comparison published by Yahoo Finance. Management expects the year to include a 53rd week, contributing about 100 basis points of growth.

The same report states that long-term trailing revenue growth was 8.1 percent and operating margin was 26.8 percent. It also identifies a counter-factor in the second quarter: Abiomed sales fell 2 percent as physicians became more selective after an external clinical trial.

Third-quarter report due October 13

Yahoo Finance identifies October 13, 2026, as the next clean check on the earnings story through Johnson & Johnson's third-quarter report. That date matters because the report can show whether the Caplyta opportunity and the broader 2026 sales plan are translating into reported results.

At the September 22, 2026 close, the stock remained USD 11.50 below its 52-week high of USD 281.07 and USD 95.45 above its 52-week low of USD 174.12. The market capitalization was USD 649.47 billion, with volume of 4.22 million shares.